Should I buy or sell Surface Oncology stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares. View SURF analyst ratings or view top-rated stocks .

How were Surface Oncology's earnings last quarter?

Surface Oncology, Inc. (NASDAQ:SURF) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The firm earned $0.39 million during the quarter.

What is Jeff Goater's approval rating as Surface Oncology's CEO?

5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com . Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Surface Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE) , CrowdStrike (CRWD) , QUALCOMM (QCOM) , Fastly (FSLY) , Intel (INTC) , Hello Group (MOMO) , NVIDIA (NVDA) , U.S. Xpress Enterprises (USX) , Xilinx (XLNX) and Genocea Biosciences (GNCA) .

When did Surface Oncology IPO?

Surface Oncology (SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

NASDAQ:SURF

Surface Oncology (SURF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Buy SURF with Qtrade

Free SURF Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.01
▼
$1.09
50-Day Range: $0.88
▼
$1.08
52-Week Range: $0.56
▼
$1.43

Volume: 1.51 million shs
Average Volume: 430,375 shs
Market Capitalization: $65.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Surface Oncology alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Surface Oncology Stock (NASDAQ:SURF)

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 which is in phase II clinical trial targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 that is in phase 1/2 clinical trials targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited and Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. As of September 8, 2023, Surface Oncology, Inc. operates as a subsidiary of Coherus BioSciences, Inc.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

SURF Stock News Headlines

April 18, 2024 | msn.com

Mill Creek clinic can now cure some skin cancers without surgery

April 18, 2024 | finance.yahoo.com

Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | msn.com

Gritstone bio (GRTS) Price Target Decreased by 37.04% to 5.78

April 17, 2024 | msn.com

Targeted therapies outperform hundreds of other drugs in 'priming' lung cancer cells for destruction

April 16, 2024 | finance.yahoo.com

Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors

April 11, 2024 | finance.yahoo.com

Provectus Biopharmaceuticals Announces Presentation of Cancer Immunotherapy PV-10 Poster for HNSCC at AACR 2024 Annual Meeting

April 10, 2024 | msn.com

Look Up and See the Future

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | finance.yahoo.com

Notable Labs Presents the Design Plan for the PPMP-Enabled Phase 2 Trial with Volasertib for Relapsed/Refractory AML at AACR 2024

April 9, 2024 | msn.com

Extracellular cell matrix stiffness may induce drug resistance of breast cancer cells

April 9, 2024 | msn.com

Targeted Therapy Revolution: For People With Cancers That Have A Special Factor Called HER2, The Drug Enhertu Is Now Approved Across Tumor Types- What To Ask Your Doctor

April 9, 2024 | finance.yahoo.com

Nvelop Therapeutics Launches with Dual Platforms for In Vivo Delivery of the Next Generation of Genetic Medicines

April 8, 2024 | businesswire.com

Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device

April 6, 2024 | finance.yahoo.com

Tempus Introduces Workspaces into its Lens Data Analytics Platform

April 5, 2024 | finance.yahoo.com

23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 4, 2024 | msn.com

Is THIS what's causing mystery rise in colon cancers among young people? New research points to bacteria in the gut linked to processed food and not eating enough fiber

April 4, 2024 | msn.com

How is Metastatic Breast Cancer Treated?

April 3, 2024 | benzinga.com

Anthony A.. Florence Jr's Net Worth

April 2, 2024 | msn.com

Investigators develop novel treatment for T-cell leukemias and lymphomas

April 2, 2024 | msn.com

Using cryo-shocked tumor cells to fight lung cancer

April 1, 2024 | msn.com

Kyverna reports first use of KYV-101 for multiple sclerosis treatment

April 1, 2024 | msn.com

Advances In Early Detection Methods For Cervical Cancer

March 30, 2024 | msn.com

Brave NJ mom conquers brain surgery fears — by singing Taylor Swift songs throughout the life-saving procedure

March 30, 2024 | msn.com

New Jersey woman sings Taylor Swift hits while awake during brain surgery: 'Eras Tour' in the O.R.

March 29, 2024 | msn.com

Mulago surgeons restore knees, joints of 33 patients

March 28, 2024 | msn.com

Clinical trial: Some sarcoma patients improve with T cell immunotherapy

See More Headlines

Receive SURF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surface Oncology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/04/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:SURF
CUSIP: N/A
CIK: 1718108
Web: www.surfaceoncology.com
Phone: (617) 714-4096
Fax: N/A
Employees: 35
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.53)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,590,000.00
Net Margins: N/A
Pretax Margin: -211.95%
Return on Equity: -107.81%
Return on Assets: -65.57%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.60
Quick Ratio: 3.60

Sales & Book Value

Annual Sales: $30 million
Price / Sales: 2.17
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.81 per share
Price / Book: 1.32

Miscellaneous

Outstanding Shares: 60,824,000
Free Float: 53,525,000
Market Cap: $65.08 million
Optionable: Not Optionable
Beta: 1.75

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Ms. Lisa McGrath
Chief People Officer
Ms. Shannon Rourke Devens
Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders

SURF Stock Analysis - Frequently Asked Questions

Should I buy or sell Surface Oncology stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Surface Oncology in the last year. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SURF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SURF, but not buy additional shares or sell existing shares.
View SURF analyst ratings or view top-rated stocks.
How were Surface Oncology's earnings last quarter?: Surface Oncology, Inc. (NASDAQ:SURF) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.04. The firm earned $0.39 million during the quarter.
What is Jeff Goater's approval rating as Surface Oncology's CEO?: 5 employees have rated Surface Oncology Chief Executive Officer Jeff Goater on Glassdoor.com. Jeff Goater has an approval rating of 100% among the company's employees. This puts Jeff Goater in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Surface Oncology own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Surface Oncology investors own include Pfizer (PFE), CrowdStrike (CRWD), QUALCOMM (QCOM), Fastly (FSLY), Intel (INTC), Hello Group (MOMO), NVIDIA (NVDA), U.S. Xpress Enterprises (USX), Xilinx (XLNX) and Genocea Biosciences (GNCA).
When did Surface Oncology IPO?: Surface Oncology (SURF) raised $84 million in an IPO on Thursday, April 19th 2018. The company issued 6,000,000 shares at a price of $13.00-$15.00 per share. Goldman Sachs, Cowen and Evercore ISI served as the underwriters for the IPO.

This page (NASDAQ:SURF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Surface Oncology (SURF) Stock Price, News & Analysis

About Surface Oncology Stock (NASDAQ:SURF)

SURF Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

SURF Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info